Adjunctive Ganaxolone Treatment (Part A) in TSC Followed by Long-term Treatment (Part B)
Completed · Phase 2
Conditions studied: Tuberous Sclerosis
In brief
To assess preliminary safety and efficacy of ganaxolone as adjunctive therapy for the treatment of primary seizure types in patients with genetically- or clinically-confirmed TSC-related epilepsy through the end of the 12 week treatment period.
Key facts
- Study ID
- NCT04285346
- Run by
- Marinus Pharmaceuticals
- People needed
- 23
- Starts
- 2020-04-08
- Expected to finish
- 2022-08-30
- Last updated by the study team
- 2023-04-04
Who can join
Age: 2 and older, up to 65. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Marinus Research Site — Los Angeles, California, United States
- Marinus Research Site — Palo Alto, California, United States
- Marinus Research Site — Boston, Massachusetts, United States
- Marinus Research Site — Livingston, New Jersey, United States
- Marinus Research Site — Durham, North Carolina, United States
- Marinus Research Site — Cincinnati, Ohio, United States
- Marinus Research Site — Houston, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.